Onset of efficacy and adverse events during Cenobamate titration period.

"CONFLICT OF INTEREST Bernhard J. Steinhoff: Consultant/advisor, speaker honoraria: Al‐Jazeera, Angelini Pharma S.p.a., B. Braun Melsungen, Desitin, Eisai, GW Pharmaceuticals, UCB Pharma, Precisis, Zogenix; Research support: Eisai, GW Pharmaceuticals, SK Life Science, Inc., UCB Pharma. Zogenix. Elinor Ben‐Menachem: Consultant/advisor: Arvelle Therapeutics, GW Pharmaceuticals, UCB Pharma, Sandoz; Research support: Eisai, SK Life Science, Inc., Zogenix; Editor, Acta Neurologica Scandinavica. Christian Brandt: Consultant/advisor: Arvelle Therapeutics, Desitin, Eisai, GW Pharmaceuticals, Idorsia, Novartis, UCB Pharma; Speaker: Eisai, SK Life Science, Inc., UCB Pharma, Upsher‐Smith, Zogenix. Irene García Morales: Nothing to disclose. William E. Rosenfeld: Consultant/advisor: SK Life Science, Inc.; Speaker: Eisai, Greenwich Biosciences (GW Pharmaceuticals), SK Life Science, Inc., Sunovion, UCB Pharma; Research support: Greenwich Biosciences, Marinus, Medtronic, Neurelis, Ovid, SK Life Science, Inc., Takeda, UCB Pharma, Upsher‐Smith. Estevo Santamarina: Consultant/advisor: Eisai, Ferrer, UCB Pharma; Speaker: Eisai, Esteve, Exeltis, UCB Pharma. José M. Serratosa: Consultant/advisor: Arvelle Therapeutics, BIAL, Eisai, GW Pharmaceuticals, Sanofi, UCB Pharma; Speaker: Arvelle Therapeutics, BIAL, Eisai, Sanofi, UCB Pharma."

"The double‐blind studies and open‐label study were funded by SK Life Science, Inc. (Paramus, NJ, USA). Study data were pooled and analyzed by Angelini S.p.a. Nicole Day, PhD, of MedVal Scientific Information Services, LLC (Princeton, NJ, USA) provided medical writing assistance, funded by Angelini S.p.a. The manuscript was prepared according to the International Society for Medical Publication Professionals' “Good Publication Practice for Communicating Company‐Sponsored Medical Research: GPP3.”"